Argenx SE stock (NL0010832176): Focus shifts to chronic ITP data and efgartigimod ramp-up

Argenx SE remains in the spotlight as investors weigh the latest clinical and commercial updates around efgartigimod for autoimmune diseases, including chronic ITP, while watching the pace of the launch and cash burn after recent quarterly results.

Argenx SE stays on the radar of biotech-focused investors as the company advances efgartigimod in multiple autoimmune indications and works to build on its existing commercial foothold in generalized myasthenia gravis (gMG). Recent quarterly updates and clinical news continue to influence sentiment toward the stock as markets assess the growth trajectory and risk profile of this mid-cap biotech name.

In its most recent quarterly report, Argenx highlighted ongoing revenue growth from efgartigimod in gMG and reiterated its focus on expanding into additional indications such as chronic immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases, according to a company update published on its investor relations site in early 2025Argenx investors as of 02/29/2025. Management emphasized both the opportunity and the investment needs related to these programs, referencing continued R&D and commercial spending in the same communicationArgenx news as of 02/29/2025.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Argenx
• Sector/industry: Biotechnology, autoimmune therapies
• Headquarters/country: Netherlands / Belgium
• Core markets: Autoimmune disease treatments, neurology and hematology specialists
• Key revenue drivers: Efgartigimod-based therapies for IgG-mediated autoimmune diseases
• Home exchange/listing venue: Nasdaq (ticker: ARGX), Euronext Brussels (ticker: ARGX)
• Trading currency: USD on Nasdaq, EUR on Euronext Brussels

Argenx SE: core business model

Argenx operates as a clinical-stage and commercial-stage biotechnology company focused on developing antibody-based therapies for severe autoimmune diseases, with efgartigimod as its flagship assetArgenx about as of 03/15/2025. The company’s business model centers on advancing a pipeline of antibody therapies targeting neonatal Fc receptor (FcRn) and other immune pathways to modulate pathogenic IgG antibodies in various diseasesArgenx R&D as of 03/15/2025.

Efgartigimod is designed to reduce IgG levels by blocking FcRn, and has been developed in both intravenous and subcutaneous formulations for multiple autoimmune indications, according to the company’s pipeline overviewArgenx pipeline as of 04/05/2025. This approach underpins the company’s strategy to leverage a single mechanism across several diseases, potentially creating scale effects in R&D and commercialization.

The company generates revenue primarily from product sales of efgartigimod in indications where it has already received regulatory approval, such as generalized myasthenia gravis in key markets, as well as from potential milestone payments and collaborations described in its financial filingsArgenx financials as of 02/29/2025. Argenx continues to invest heavily in clinical trials and commercial infrastructure to expand its indications and geographic reach, which influences its near-term profitability metrics.

Main revenue and product drivers for Argenx SE

The main revenue driver for Argenx is efgartigimod, marketed under brand names that vary by region for the treatment of generalized myasthenia gravis and other approved uses, according to regional label descriptions referenced by the companyArgenx products as of 03/30/2025. Expansion into additional autoimmune conditions, including chronic ITP and other IgG-mediated disorders, represents a key growth avenue highlighted in corporate presentationsArgenx presentations as of 04/10/2025.

In its latest reported fiscal year, Argenx noted increasing net product sales driven by uptake of efgartigimod in its initial markets, while also reporting ongoing net losses due to substantial R&D and commercial expenditures, according to its annual report filed in early 2025 for the 2024 financial yearArgenx annual report as of 03/07/2025. Management pointed out that future revenue growth is expected to rely not only on increasing penetration within gMG but also on label expansions and approvals in new indications.

Beyond efgartigimod, Argenx maintains a pipeline of earlier-stage antibody programs that target additional immune pathways, which the company views as potential longer-term revenue contributors, as described in its R&D overviewArgenx R&D as of 03/15/2025. These programs are at various stages of clinical development and are subject to typical biotech risks related to trial outcomes, regulatory review, and competitive dynamics.

Conclusion

Argenx SE offers investors exposure to a focused autoimmune franchise built around efgartigimod, with current revenues primarily from generalized myasthenia gravis and potential upside from additional indications such as chronic ITP and other IgG-mediated diseases. The company’s strategy relies on leveraging its FcRn-targeting platform across multiple autoimmune conditions while continuing to invest in R&D and commercial infrastructure, which weighs on near-term profitability. For US investors following mid-cap biotech, the dual listing on Nasdaq and Euronext Brussels, combined with a growing commercial footprint in autoimmune neurology and hematology, makes Argenx a name that is closely tied to clinical trial outcomes, regulatory decisions, and the pace of adoption in its approved indications.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.